Gentamicin pharmacokinetics in diabetic dogs

S. A. Brown, Richard W Nelson, C. Scott-Moncrieff

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Reduction of the prolonged terminal elimination phase of gentamicin may be caused by diabetes mellitus, irrespective of the model of diabetes. To test this hypothesis, five normal dogs, three dogs with alloxan-induced diabetes mellitus, and four dogs with naturally occurring diabetes mellitus (all of which were given exogenous insulin to control hyperglycemia) were given 4.4 mg/kg gentamicin intravenously. Serum pharmacokinetics were analyzed using non-compartmental pharmacokinetics assuming a sum of exponential terms. Gentamicin pharmacokinetics during the first 8 h were the same in normal and diabetic dogs. Over 7 days, MRT in normal dogs (5830 ± 2970 min, mean ± SD) was longer (P < 0.01) than in diabetic dogs (136 ± 164 min). In diabetic dogs, Cl(s) was greater (3.01 ± 0.86 ml/min/kg) than in normal dogs (1.45 ± 0.11 ml/min/kg; P < 0.01), whereas V(d(ss)) was smaller in diabetic dogs (0.405 ± 0.508 l/kg) than in normal dogs (8.56 ± 4.48 l/kg; P < 0.01). Serum gentamicin concentrations were less than 0.020 μg/ml by 2 days in all of the diabetic dogs, but were 0.048 ± 0.018 μg/ml at 7 days in normal dogs. Thus, diabetes mellitus, either induced by alloxan administration or naturally occurring, abolished the terminal elimination phase of gentamicin disposition in a non-rodent species.

Original languageEnglish (US)
Pages (from-to)90-95
Number of pages6
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume14
Issue number1
StatePublished - 1991
Externally publishedYes

Fingerprint

gentamicin
Gentamicins
pharmacokinetics
Pharmacokinetics
Dogs
dogs
diabetes mellitus
Diabetes Mellitus
alloxan
Alloxan
Experimental Diabetes Mellitus
hyperglycemia
Serum
Hyperglycemia
diabetes
insulin
Insulin

ASJC Scopus subject areas

  • Pharmacology
  • veterinary(all)

Cite this

Gentamicin pharmacokinetics in diabetic dogs. / Brown, S. A.; Nelson, Richard W; Scott-Moncrieff, C.

In: Journal of Veterinary Pharmacology and Therapeutics, Vol. 14, No. 1, 1991, p. 90-95.

Research output: Contribution to journalArticle

Brown, S. A. ; Nelson, Richard W ; Scott-Moncrieff, C. / Gentamicin pharmacokinetics in diabetic dogs. In: Journal of Veterinary Pharmacology and Therapeutics. 1991 ; Vol. 14, No. 1. pp. 90-95.
@article{de5221332d4a4c3d8012a3451060d507,
title = "Gentamicin pharmacokinetics in diabetic dogs",
abstract = "Reduction of the prolonged terminal elimination phase of gentamicin may be caused by diabetes mellitus, irrespective of the model of diabetes. To test this hypothesis, five normal dogs, three dogs with alloxan-induced diabetes mellitus, and four dogs with naturally occurring diabetes mellitus (all of which were given exogenous insulin to control hyperglycemia) were given 4.4 mg/kg gentamicin intravenously. Serum pharmacokinetics were analyzed using non-compartmental pharmacokinetics assuming a sum of exponential terms. Gentamicin pharmacokinetics during the first 8 h were the same in normal and diabetic dogs. Over 7 days, MRT in normal dogs (5830 ± 2970 min, mean ± SD) was longer (P < 0.01) than in diabetic dogs (136 ± 164 min). In diabetic dogs, Cl(s) was greater (3.01 ± 0.86 ml/min/kg) than in normal dogs (1.45 ± 0.11 ml/min/kg; P < 0.01), whereas V(d(ss)) was smaller in diabetic dogs (0.405 ± 0.508 l/kg) than in normal dogs (8.56 ± 4.48 l/kg; P < 0.01). Serum gentamicin concentrations were less than 0.020 μg/ml by 2 days in all of the diabetic dogs, but were 0.048 ± 0.018 μg/ml at 7 days in normal dogs. Thus, diabetes mellitus, either induced by alloxan administration or naturally occurring, abolished the terminal elimination phase of gentamicin disposition in a non-rodent species.",
author = "Brown, {S. A.} and Nelson, {Richard W} and C. Scott-Moncrieff",
year = "1991",
language = "English (US)",
volume = "14",
pages = "90--95",
journal = "Journal of Veterinary Pharmacology and Therapeutics",
issn = "0140-7783",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Gentamicin pharmacokinetics in diabetic dogs

AU - Brown, S. A.

AU - Nelson, Richard W

AU - Scott-Moncrieff, C.

PY - 1991

Y1 - 1991

N2 - Reduction of the prolonged terminal elimination phase of gentamicin may be caused by diabetes mellitus, irrespective of the model of diabetes. To test this hypothesis, five normal dogs, three dogs with alloxan-induced diabetes mellitus, and four dogs with naturally occurring diabetes mellitus (all of which were given exogenous insulin to control hyperglycemia) were given 4.4 mg/kg gentamicin intravenously. Serum pharmacokinetics were analyzed using non-compartmental pharmacokinetics assuming a sum of exponential terms. Gentamicin pharmacokinetics during the first 8 h were the same in normal and diabetic dogs. Over 7 days, MRT in normal dogs (5830 ± 2970 min, mean ± SD) was longer (P < 0.01) than in diabetic dogs (136 ± 164 min). In diabetic dogs, Cl(s) was greater (3.01 ± 0.86 ml/min/kg) than in normal dogs (1.45 ± 0.11 ml/min/kg; P < 0.01), whereas V(d(ss)) was smaller in diabetic dogs (0.405 ± 0.508 l/kg) than in normal dogs (8.56 ± 4.48 l/kg; P < 0.01). Serum gentamicin concentrations were less than 0.020 μg/ml by 2 days in all of the diabetic dogs, but were 0.048 ± 0.018 μg/ml at 7 days in normal dogs. Thus, diabetes mellitus, either induced by alloxan administration or naturally occurring, abolished the terminal elimination phase of gentamicin disposition in a non-rodent species.

AB - Reduction of the prolonged terminal elimination phase of gentamicin may be caused by diabetes mellitus, irrespective of the model of diabetes. To test this hypothesis, five normal dogs, three dogs with alloxan-induced diabetes mellitus, and four dogs with naturally occurring diabetes mellitus (all of which were given exogenous insulin to control hyperglycemia) were given 4.4 mg/kg gentamicin intravenously. Serum pharmacokinetics were analyzed using non-compartmental pharmacokinetics assuming a sum of exponential terms. Gentamicin pharmacokinetics during the first 8 h were the same in normal and diabetic dogs. Over 7 days, MRT in normal dogs (5830 ± 2970 min, mean ± SD) was longer (P < 0.01) than in diabetic dogs (136 ± 164 min). In diabetic dogs, Cl(s) was greater (3.01 ± 0.86 ml/min/kg) than in normal dogs (1.45 ± 0.11 ml/min/kg; P < 0.01), whereas V(d(ss)) was smaller in diabetic dogs (0.405 ± 0.508 l/kg) than in normal dogs (8.56 ± 4.48 l/kg; P < 0.01). Serum gentamicin concentrations were less than 0.020 μg/ml by 2 days in all of the diabetic dogs, but were 0.048 ± 0.018 μg/ml at 7 days in normal dogs. Thus, diabetes mellitus, either induced by alloxan administration or naturally occurring, abolished the terminal elimination phase of gentamicin disposition in a non-rodent species.

UR - http://www.scopus.com/inward/record.url?scp=0025982106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025982106&partnerID=8YFLogxK

M3 - Article

C2 - 2038099

AN - SCOPUS:0025982106

VL - 14

SP - 90

EP - 95

JO - Journal of Veterinary Pharmacology and Therapeutics

JF - Journal of Veterinary Pharmacology and Therapeutics

SN - 0140-7783

IS - 1

ER -